



- (51) **International Patent Classification:**  
*C12N 9/40* (2006.01) *A61K 35/18* (2015.01)
- (21) **International Application Number:**  
PCT/US2014/061789
- (22) **International Filing Date:**  
22 October 2014 (22.10.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/894,879 23 October 2013 (23.10.2013) US  
61/901,942 8 November 2013 (08.11.2013) US
- (71) **Applicant:** GENZYME CORPORATION [US/US]; 500 Kendall Street, Cambridge, Massachusetts 02142 (US).
- (72) **Inventors:** LEE, Karen; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). HWANG, Christopher; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US). DEMARIA, Christine; c/o Sanofi, 55 Corporate Drive, Mail Code: 55A-505A, Bridgewater, New Jersey 08807 (US).
- (74) **Agents:** REITER, Tiffany et al.; Fish & Richardson, P.C., P.O. Box 1022, Minneapolis, Minnesota 554440 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,

HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

**(88) Date of publication of the international search report:**

3 September 2015


**(54) Title:** RECOMBINANT GLYCOPROTEINS AND USES THEREOF

FIG. 20

(57) **Abstract:** Provided herein are recombinant glycoproteins (e.g., recombinant human  $\alpha$ -galactosidase-A proteins) with an altered (e.g., improved) glycosylation profile, and pharmaceutical compositions and kits including one or more of these proteins. Also provided are methods of generating a mammalian cell useful for recombinant expression of a glycoprotein (e.g., recombinant human  $\alpha$ -galactosidase-A), methods of producing recombinant glycoproteins, and methods of treatment that include administering to a subject at least one of the recombinant glycoproteins (e.g., recombinant human  $\alpha$ -galactosidase-A protein).